Good luck, SEAH. This is definitely a second chance for those who missed out prior to FDA approval. I'm well and truly loaded up already.
I'd never thought we'd be at these levels again after FDA. Cannacord did not show any CR over the next few years in their models. Interestingly, they organised the CR. Maybe they have a second 'black' analyst report for their clients and the front one on their website.
Though I expected some kind of small raise, this is well beyond my expectations. If they cared about dilution, they would have raised half now and more later when the SP should be higher on the back of sales. Tells me they don't think take up will be as fast as Oz and/or there are significant more costs in getting this company off the ground than what's being presented. This is a subtle theme I'm picking up from investor communication. Need to add 20-30% on top of any communication to get an accurate picture.
AXP Price at posting:
99.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)